Printer Friendly

DIMENSIONAL MEDICINE REPORTS FOURTH QUARTER AND YEAR-END RESULTS

 DIMENSIONAL MEDICINE REPORTS FOURTH QUARTER AND YEAR-END RESULTS
 MINNEAPOLIS, June 1 /PRNewswire/ -- Dimensional Medicine, Inc. (NASDAQ: DMED)(DMI), a Minneapolis-based developer and marketer of radiology-related systems, reported operating revenues for the fourth quarter ended March 31, 1992, of $1,720,294 compared to revenues of $1,007,012 for the prior year's fourth quarter. Net loss for the quarter was $316,760, or $.08 per share, compared to the previous year's fourth quarter net loss of $1,317,206, or $.29 per share.
 For the fiscal year ended March 31, 1992, DMI's operating revenues totaled $6,126,802 compared to $5,039,217 for the prior year, a 22 percent increase. The net loss for the year was $446,830, or $.12 per share, compared to $2,483,980, or $.44 per share for the prior fiscal year.
 The results for the 1992 fourth quarter and year end include $343,888 of costs associated with an unfavorable trial ruling on a 1987 imaging system contract.
 David H. Littlefield, president and chief executive officer commented, "The fourth quarter and year-end results validated an excellent turn-around year for the company. Only the very disappointing litigation result prevented us from reporting our third consecutive profitable quarter. Solid revenue gains and cost controls add to our confidence of further improvements in operating results in the coming year."
 Dimensional Medicine, Inc. designs, develops and markets computerized peripheral equipment and systems to the radiology medical market. The company is headquartered in Minnetonka, Minn.
 DIMENSIONAL MEDICINE, INC.
 RESULTS OF OPERATIONS
 (Unaudited)
 Three Months Ended Year Ended
 3/31/92 3/31/91 3/31/92 3/31/91
 Operating revenues $1,720,294 $1,007,012 $6,126,802 $5,039,217
 Operating costs and
 expenses 1,691,199 2,240,391 6,214,823 7,169,766
 Operating income (loss) 29,095 (1,233,379) (88,021) (2,128,549)
 Other expense-net (a) 345,855 83,827 358,809 355,431
 Net (loss) $(316,760)$(1,317,206) $(446,830)$(2,483,980)
 Net income (loss) per
 share $(.08) $(.29) $(.12) $(.44)
 Weighted average number
 of shares outstanding 3,673,346 4,466,679 3,673,346 5,649,072
 (a) The 1992 amounts include $343,888 of costs and expenses incurred in settlement of litigation commenced in 1990.
 -0- 6/1/92
 /CONTACT: Richard G. May of Dimensional Medicine, 612-938-8280/
 (DMED) CO: Dimensional Medicine, Inc. ST: Minnesota IN: MTC SU: ERN


AL -- MN019 -- 5947 06/01/92 17:47 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 1, 1992
Words:415
Previous Article:NINTENDO WINS FEDERAL ANTITRUST SUIT
Next Article:ENRON FILES REGISTRATION STATEMENT FOR PUBLIC OFFERING OF LIMITED PARTNERSHIP UNITS IN LIQUIDS PIPELINES
Topics:


Related Articles
DIMENSIONAL MEDICINE REPORTS SIGNIFICANT IMPROVEMENT AND CONTINUED PROFITABILITY IN THIRD QUARTER RESULTS
DIMENSIONAL MEDICINE REPORTS FIRST QUARTER RESULTS
DIMENSIONAL MEDICINE REPORTS THIRD QUARTER RESULTS
DIMENSIONAL MEDICINE REPORTS FOURTH QUARTER AND YEAR-END RESULTS
DIMENSIONAL MEDICINE REPORTS FOURTH QUARTER AND YEAR-END RESULTS
DIMENSIONAL MEDICINE REPORTS FIRST QUARTER RESULTS
DIMENSIONAL MEDICINE REPORTS THIRD QUARTER RESULTS
DIMENSIONAL MEDICINE REPORTS FOURTH QUARTER AND YEAR-END RESULTS
DIMENSIONAL MEDICINE REPORTS FIRST QUARTER RESULTS
DIMENSIONAL MEDICINE REPORTS EXPECTED FOURTH QUARTER AND YEAR-END RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters